Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
about
A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors.New agents for the management of resistant metastatic breast cancer.The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target.
P2860
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Sacituzumab govitecan (IMMU-13 ...... : Safety and pharmacokinetics.
@ast
Sacituzumab govitecan (IMMU-13 ...... : Safety and pharmacokinetics.
@en
type
label
Sacituzumab govitecan (IMMU-13 ...... : Safety and pharmacokinetics.
@ast
Sacituzumab govitecan (IMMU-13 ...... : Safety and pharmacokinetics.
@en
prefLabel
Sacituzumab govitecan (IMMU-13 ...... : Safety and pharmacokinetics.
@ast
Sacituzumab govitecan (IMMU-13 ...... : Safety and pharmacokinetics.
@en
P2093
P2860
P356
P1433
P1476
Sacituzumab govitecan (IMMU-13 ...... : Safety and pharmacokinetics.
@en
P2093
Aditya Bardia
Alexander N Starodub
Allyson J Ocean
David M Goldenberg
Ingrid A Mayer
Linda T Vahdat
Michael Guarino
Pius Maliakal
Serengulam V Govindan
Steven J Isakoff
P2860
P304
P356
10.1002/CNCR.30789
P407
P577
2017-05-30T00:00:00Z